参麦注射液对慢性心力衰竭患者长期预后的影响:多中心大样本长期随访回顾性队列研究
该多中心回顾性队列研究基于医院信息系统数据,纳入1211例慢性心衰患者,最终随访1047例,比较参麦注射液暴露(用药>7天)与非暴露组的长期预后。结果显示暴露组心源性死亡和心衰再入院率更低,NYHA分级、LVEF和NT-ProBNP改善更优,提示在标准化西药治疗基础上联用参麦注射液可改善长期预后。
要点
- 参麦注射液暴露组心源性死亡率和心衰再入院率均低于非暴露组。
- 暴露组NYHA分级下降比例、LVEF和NT-ProBNP改善值均优于非暴露组。
- Cox回归显示参麦注射液是心源性死亡和心衰再入院的保护因素。
核心结论
- 在标准化西药治疗基础上联用参麦注射液可有效降低慢性心衰患者心源性死亡率和再入院率,改善长期预后。
研究设计与样本
- 多中心、大样本、长期随访的回顾性队列研究,利用医院信息系统提取慢性心衰患者数据。
- 共纳入1211例符合条件的慢性心衰患者,最终成功随访1047例。
- 暴露组为参麦注射液应用超过7天者,非暴露组为未联用参麦注射液而使用标准化西药治疗及中成药或汤剂者。
主要发现
- 治疗后暴露组与非暴露组NYHA分级下降比例分别为64.30%和43.45%。
- 暴露组与非暴露组LVEF改善值分别为8.89%和7.91%,NT-ProBNP改善值分别为909 pg/mL和735 pg/mL。
- 参麦注射液暴露后心源性死亡率从15.43%降至10.18%,心衰再入院率从38.93%降至32.37%。
- Kaplan-Meier分析显示参麦注射液与心源性死亡的log-rank P值为0.014,与心衰再入院的log-rank P值为0.025。
- Cox回归分析表明,心源性死亡的风险因素包括年龄、心肌病、糖尿病和NYHA分级,保护因素包括β受体阻滞剂、醛固酮受体拮抗剂、中成药/汤剂和参麦注射液;心衰再入院的风险因素包括年龄、心肌病和NYHA分级,参麦注射液为保护因素。
临床怎么用
- 对于慢性心衰患者,可在标准化西药治疗基础上考虑联用参麦注射液以改善长期预后。
局限性
- 本研究为回顾性队列研究,可能存在选择偏倚和混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore the effect of Shenmai Injection (SMI) on the long-term prognosis of patients with chronic heart failure (CHF). METHODS: The Hospital Information System was used to extract data of CHF patients, and the retrospective cohort study was conducted for analysis. In non-exposed group, standardized Western medicine treatment and Chinese patent medicine or decoction were applied without combination of SMI while in the exposed group, SMI were applied for more than 7 days. Evaluation indicators are followed with New York Heart Association functional classification (NYHA classification), left ventricular ejection fraction (LVEF), N-terminal brain natriuretic peptide precursor (NT-ProBNP), cardiogenic death and heart failure (HF) readmission. Statistical analysis includes Kaplan-Meier analysis and Cox regression which are used to explore the relationship between SMI and outcome events. RESULTS: A total of 1,211 eligible CHF patients were involved and finally 1,047 patients were followed up successfully. After treatment, the cases of NYHA classification decline in the exposed and non-exposed groups accounted for 64.30% and 43.45%, respectively; the improvement values of LVEF were 8.89% and 7.91%, respectively; the improvement values of NT-ProBNP were 909 pg/mL and 735 pg/mL, respectively. After exposure on SMI, the rates of cardiogenic death and HF readmission reduced from 15.43% to 10.18% and 38.93% to 32.37%. According to Kaplan-Meier analysis, the log-rank P value of SMI and cardiogenic death was 0.014, while the counterpart of SMI and HF readmission was 0.025. Cox regression analysis indicated that for cardiogenic death, age, cardiomyopathy, diabetes, and NYHA classification were risk factors while β-blockers, aldosterone receptor antagonists, Chinese patent medicine/decoction and SMI were protective factors. Likewise, for HF readmission, age, cardiomyopathy, and NYHA classification were risk factors while SMI was a protective factor. CONCLUSION: Combination with SMI on the standardized Western medicine treatment can effectively reduce cardiogenic mortality and readmission rate in CHF patients, and thereby improve the long-term prognosis.
引用
- Guan H, Dai GH, Gao WL, et al. Effect of Shenmai Injection on Long-Term Prognosis of Patients with Chronic Heart Failure: A Multicenter, Large Sample Capacity, Long-Term Follow-Up Retrospective Cohort Study. Chin J Integr Med. 2021. PMID: 34874517. doi:10.1007/s11655-021-2875-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。